Market LIVE
Published markets; coverage varies by country
Product profile · United States

TALZENNA

 ·  Patent Litigation & Settlement History ↓

IngredientTALAZOPARIB TOSYLATE
Application typeNDA
Application217439
Product003
Dosage formCAPSULE
RouteORAL
StrengthEQ 0.35MG BASE
Approval date2024-03-07
Marketing statusPrescription
Status event—
ApplicantPFIZER
Product source

Current GenericRadar decision

Year2032
SelectionCANDIDATE
ReviewFINAL
Anchor typePATENT
Anchor date2032-10-16
Patent anchor2032-10-16
Exclusivity anchor—
Protection date—
First Final ANDA—
Status event—

QUALIFYING_ANCHOR_NO_LATER_RIGHTS

Patent estate

PatentEffective dateOfficial listingTRUE_DSDS gradeClaim classification / basisPTEPEDFamily
107800882029-07-27U U-3651NNU
———
84206502029-07-27DS/DP —YNTRUE_DS
———
98209852029-07-27U U-2437NNU
———
101898372031-10-20DS/DP —NNDP
———
87353922031-10-20DS/DP —NNDP
———
80129762032-10-16DS/DP —YNTRUE_DS
———
80129762032-10-16DS;DP ————
OB official listing only. TRUE_DS/DS-equivalent/claim scope/PTE-PED effective anchor remains unconfirmed.
———

Regulatory exclusivity

CodeStart dateEnd dateScopeEntire productAll indicationsFull coverage dateCombinationSource
No exclusivity facts are recorded in this product snapshot.

2026-10-10 · NO_RECORD_IN_CURRENT_SNAPSHOT · Historical coverage: NOT_COMPLETE

Generic approval evidence

Application / productEventFinal dateTentative dateApplicantAuthorized genericExact mappingSource
No generic approval facts are linked to this product.

Market Entry Information

API filings, authorized generics and linked regulatory milestones.

API Master Files & Certifications 0 records

Ingredient-level registrations from linked public manufacturer portfolios. A filing does not establish supply to this finished product. DMFs are not FDA approvals.

APIHolder / manufacturerHolder countryFiling typeNumberStatusFiled dateAvailable for referenceSourceLast verified
No master-file or certification records are linked through public manufacturer portfolios.

Authorized Generics 0 records

Authorized generics are shown separately from independent ANDA approvals.

Application / productApplicantEvent / status First marketed Product mappingSourceLast verified
No authorized-generic records are linked to this product.

Tentative ANDA Approvals 0 records

Tentative approval is not final approval. Historical tentative approvals remain visible after a linked final approval.

Application / productApplicantEvent / status Tentative date Follow-up final approvalProduct mappingSourceLast verified
No tentative-approval records are linked to this product.

Paragraph IV Challenges 0 records

Paragraph IV challenges below are sourced from legal records separately from FDA approvals. An ANDA filing, lawsuit or settlement does not establish final approval or commercial launch.

Application / productApplicantEvent / status Certification event date Product mappingSourceLast verified
No structured Paragraph IV certification events are linked in the available approval evidence.

Final ANDA Approvals 0 records

Approval dates do not establish commercial launch. Product mapping is shown for each linked record.

Application / productApplicantEvent / status Final approval date Product mappingSourceLast verified
No final-approval records are linked to this product.
Decision evidence (1)
TypeDateRoleBasisSource
REGULATORY_STATUS2032-10-16CANONICAL_DECISIONQUALIFYING_ANCHOR_NO_LATER_RIGHTSSource
Independent legal-event information

Litigation & Settlement History

Settlement launch rights generally apply only to the named parties and product scope. These records do not change GenericRadar patent/exclusivity anchors or current decisions.

No litigation or settlement record currently linked to this product.